Psilocybin Trial Shows Durable Results for Treatment-Resistant Depression

Compass Pathways released 26-week follow-up data from its Phase 3 COMP006 trial in July 2026, showing that COMP360, its synthetic psilocybin compound, produced rapid and durable improvements in patients with treatment-resistant depression.

Treatment-resistant depression affects people who have not responded to at least two standard antidepressant treatments. It is one of the most difficult conditions in psychiatry to treat, and patients often cycle through medications for years without finding relief.

The COMP006 trial enrolled patients across multiple countries. Participants received a single dose of COMP360 in a controlled clinical setting with trained therapists present before, during, and after the session. The 26-week data showed that many patients who responded to the treatment maintained their improvement over the follow-up period.

Compass Pathways has been running clinical trials on psilocybin since 2018. The company received Breakthrough Therapy designation from the U.S. Food and Drug Administration, which is intended to speed development of treatments for serious conditions.

The results come as the field of psychedelic medicine continues to attract both scientific interest and regulatory attention. Australia became the first country to authorize psilocybin for therapeutic use in 2023. Several U.S. states have moved to decriminalize or regulate psilocybin, and Oregon launched a supervised psilocybin services program in 2023.

Researchers caution that psilocybin therapy is not a simple pill. The treatment requires trained therapists, a controlled setting, and careful patient selection. Side effects can include anxiety, confusion, and in rare cases, more serious psychological reactions. The therapy is not appropriate for people with a personal or family history of psychosis.